Voyager Therapeutics (VYGR) Research & Development (2014 - 2026)
Voyager Therapeutics (VYGR) posted Research & Development of $24.6 million for Q1 2026, down 31.57% sequentially from $36.0 million in Q4 2025, and down 21.96% YoY from $31.5 million in Q1 2025.
Voyager Therapeutics (VYGR) Research & Development (2014 - 2026) Analysis & Trends
Voyager Therapeutics has reported Research & Development for 13 years, with the latest figure at $24.6 million in Q1 2026.
- Quarterly Research & Development fell 21.96% year-over-year to $24.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $127.8 million (down 3.07% YoY) and the FY2025 annual result came in at $134.7 million, up 5.74% from the prior year.
- Research & Development retreated to $24.6 million in Q1 2026 per VYGR's latest filing, from $36.0 million in the prior quarter.
- Over five years, Research & Development peaked at $36.0 million in Q4 2025 and troughed at $12.5 million in Q2 2022.
- A 5-year average of $25.9 million and a median of $25.9 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2023: Research & Development tumbled 35.79% in 2022, then jumped 77.01% in 2023.
- Over 5 years, Research & Development stood at $14.6 million in 2022, then surged by 77.01% to $25.8 million in 2023, then jumped by 38.15% to $35.6 million in 2024, then advanced by 1.04% to $36.0 million in 2025, then slumped by 31.57% to $24.6 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $24.6 million, $36.0 million, and $35.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Voyager Therapeutics | 201.32 Mn | 84.98 Mn | - | 22.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.04 Mn |
| Mar 31, 2026 | 24.60 Mn |
| Dec 31, 2025 | 35.95 Mn |
| Sep 30, 2025 | 35.87 Mn |
| Jun 30, 2025 | 31.33 Mn |
| Mar 31, 2025 | 31.53 Mn |
| Dec 31, 2024 | 35.58 Mn |
| Sep 30, 2024 | 30.24 Mn |
| Jun 30, 2024 | 34.45 Mn |
| Mar 31, 2024 | 27.09 Mn |
| Dec 31, 2023 | 25.76 Mn |
| Sep 30, 2023 | 25.86 Mn |
| Jun 30, 2023 | 21.99 Mn |
| Mar 31, 2023 | 18.57 Mn |
| Dec 31, 2022 | 14.55 Mn |
| Sep 30, 2022 | 19.34 Mn |
| Jun 30, 2022 | 12.53 Mn |
| Mar 31, 2022 | 14.35 Mn |
| Dec 31, 2021 | 14.02 Mn |
| Sep 30, 2021 | 17.91 Mn |